Crizotinib PLOS One File final.sav

Total body metabolic tumor response in ALK positive non-small-cell lung cancer patients treated with crizotini

Baseline patient characteristics.

<p>Baseline patient characteristics.</p

Baseline ¹⁸F-FDG PET and CT tumor response measurements with PERCIST and EORTC criteria and progression-free survival per patient with ALK positive NSCLC.

<p>Baseline ¹⁸F-FDG PET and CT tumor response measurements with PERCIST and EORTC criteria and progression-free survival per patient with ALK positive NSCLC.</p

¹⁸F-FDG maximum intensity projection of patient 2 and 8 prior to (A, B) and after 6 weeks of treatment with crizotinib (C, D).

<p>Scale is from 0–15 SUV. These images illustrate the clinically dramatic decrease in ¹⁸F-FDG uptake, with both patients having a PMR according to both PERCIST criteria and the EORTC recommendations.</p